12 credit hours (CME) have been awarded for the Falk Symposium 174 by the European Union of Medical Specialists (UEMS) – European Board of Gastroenterology (EBG).
Preface

Gut and liver are closely related, sharing the location in the abdominal cavity, the blood supply and their metabolic and nutritive functions. Their relation is much more intense than previously thought due to signal molecules from the gut reaching the liver where they are modified or degraded. Both organs are involved in maintaining homeostasis between the organism and the outside world as represented by the gut flora with help of the innate and the adaptive immune system.

Diseases of the gut may affect the liver and the biliary system. On the other hand diseases of the liver influence the gut and its luminal contents leading to changes of the flora and the intestinal barrier.

This symposium discusses on two days inflammatory bowel diseases and chronic liver disease and its consequences. Based on pathogenetic considerations diagnosis and treatment are covered in eight sessions. Four State of the Art Lectures will summarize important consequences and outlooks. The scientific organizers hope that the program attracts the interest of many colleagues and that we will have active and lively discussions.

The scientific organizers.
Gut and Liver

Shangri-La’s Kerry Centre Hotel
Beijing, P. R. China

Registration:
Thursday, August 26, 2010
16.00 – 21.00 h
at the congress office

Scientific Organization:
C.-W. Chen, Shanghai (P. R. China)
J. Cheng, Beijing (P. R. China)
P. Ginès, Barcelona (Spain)
Q. Ouyang, Chengdu (P. R. China)
J. Schölmerich, Regensburg (Germany)

Information:
Prof. Dr. Jürgen Schölmerich
Klinik für Innere Medizin I
Klinikum der
Universität Regensburg
93042 Regensburg
Germany
Telephone: +49 (0) 941/944 70 01
Telefax: +49 (0) 941/944 70 02
E-mail: juergen.schoelmerich@klinik.uni-regensburg.de

Official Language:
English and Chinese
(Simultaneous translation)

Poster session:
For details see page 10

Congress Venue:
Shangri-La’s Kerry Centre Hotel
1 Guang Hua Road
100020 Beijing
P. R. China
Friday, August 27, 2010

Inflammatory bowel disease

8.30 Welcome

Session I
Pathophysiology

Chair: P. Gibson, Melbourne; B. Xia, Wuhan

9.00 IBD genetics around of the world

9.30 The barrier as etiologic and pathophysiologic principle

10.00 Environmental factors: Different in China versus the western world?

10.30 Coffee break with poster session

Session II
Diagnostics

Chair: S. Feuerbach, Regensburg; K.-C. Wu, Xi’an

11.00 Modern endoscopy and radiology

11.30 Serological markers in IBD

12.00 Stool markers / microbiology

12.30 State-of-the-Art-Lecture I
Chair: J.-J. Zheng, Suzhou

New insights into IBD epidemiology – Are there any lessons for treatment?

13.00 Lunch break with poster session
Friday, August 27, 2010

Session III
Therapeutics I: Ulcerative colitis
Chair: J.-M. Qian, Beijing; J. D. Sollano, Manila

14.00 Oral/rectal or combination 5-ASA? P. Marteau, Paris

14.30 The choice of the immunosuppressant G. Mantzaris, Athens

15.00 When is surgery indicated? Q. Ouyang, Chengdu

15.30 Coffee break with poster session

Session IV
Therapeutics II: Crohn’s disease
Chair: P.-J. Hu, Guangzhou; S. R. Targan, Los Angeles

16.00 Basic treatment and prediction of a severe course M. Simadibrata, Jakarta

16.30 Immunosuppressive therapy T. Hibi, Tokyo

17.00 Surgical options? W. Bemelman, Amsterdam

17.30 Case discussion
Chair: M. Watanabe, Tokyo
Discussion by speakers of session IV

18.00 State-of-the-Art-Lecture II
Chair: Y.-Z. Yuan, Shanghai
What should we expect from future therapies? S. B. Hanauer, Chicago

18.30 End of afternoon session
Liver diseases

Session V
Chronic liver inflammation

Chair: X.-H. Miao, Shanghai; G. Paumgartner, Munich

9.00 New antiviral therapies in the management of hepatitis C virus infection
S. Zeuzem, Frankfurt

9.30 Management of hepatitis C, West and East
L. Wei, Beijing

10.00 Pathogenesis and management of non-alcoholic steatohepatitis
G. C. Farrell, Canberra

10.30 Coffee break with poster session

Session VI
Chronic liver failure – Clinical aspects

Chair: P. Ginès, Barcelona; G.-Q. Wang, Beijing

11.00 Acute-on-chronic liver failure – Pathogenesis and diagnosis
R. Moreau, Clichy

11.30 Emerging role of adrenal insufficiency in chronic liver failure
M.-H. Tsai, Taipei

12.00 Pathogenesis and clinical significance of cirrhotic cardiomyopathy
S. S. Lee, Calgary

12.30 State-of-the-Art-Lecture III
Chair: E. J. Gane, Auckland
Management of chronic hepatitis B infection
C. L. Lai, Hong Kong

13.00 Lunch break with poster session
Saturday, August 28, 2010

Session VII
Chronic liver failure management

Chair: J.-L. Hou, Guangzhou; F. Wong, Toronto

14.00 Renal complications  V. Arroyo-Perez, Barcelona
14.30 Management of bacterial infections  K.-H. Han, Seoul
15.00 Hepatic encephalopathy  D. Häussinger, Dusseldorf
15.30 Coffee break with poster session

Session VIII
Liver cancer

Chair: J. Cheng, Beijing; A. M. Di Bisceglie, St. Louis

16.00 The antiviral therapy for decompensated hepatitis B related cirrhosis  Q.-C. Fu, Shanghai
16.30 Diagnosis and stratification of hepatocellular carcinoma  M. Colombo, Milano
17.00 The diagnosis and management of small HCC  F. Shen, Shanghai
17.30 Case discussion
(Presentation of case by a local fellow, discussion by moderators and speakers of session VIII)

18.00 State-of-the-Art-Lecture IV
Chair: J. Fan, Shanghai
Management of hepatocellular carcinoma  G. J. Gores, Rochester

18.30 Presentation of Poster Prizes  P. Ginès, Barcelona
J. Schölmerich, Regensburg

18.45 End of meeting
**Poster Session**

Posters will be exhibited on August 27–28, 2010, at the Shangri-La Hotel Beijing. The authors will be in attendance during coffee and lunch breaks on both days.

**Gut**

1. Characteristics of ulcerative colitis in country with low prevalence of inflammatory bowel disease

2. Impaired endothelial function in patients with inflammatory bowel disease
   H. Akpinar, H. Kayahan, I. Sari, N. Cullu, M. Akarsu, S. Demir, F. Yüksel, Y. Göktyay, B. Ünsal (Izmir, TR)

3. Prevalence of microscopic colitis in patients with chronic non-bloody diarrhea and normal colonoscopy in Tugurejo Hospital Semarang, Indonesia
   J.A. Auwyang, M. Simadibrata, A. Tarius (Semarang, Jakarta, RI)

4. Prevalence of mutations in thiopurine S-methyltransferase gene among Slovak IBD patients
   M. Bátovsky, B. Desatová, T. Hlavaty, M. Huorka, Z. Zelinková, P. Celec, D. Baláková, L. Kádesi, M. Gregus, M. Zakuciová, M. Hlista, M. Horáková (Bratislava, Nitra, Kosice, Trencin, Martin, SK; Rotterdam, NL)

5. Mutations in thiopurine S-methyltransferase gene increases risk of azathioprine-induced leukopenia in Slovak IBD patients
   M. Bátovsky, B. Desatová, T. Hlavaty, M. Huorka, Z. Zelinková, P. Celec, D. Baláková, L. Kádesi, M. Gregus, M. Zakuciová, M. Hlista, M. Horáková (Bratislava, Nitra, Kosice, Trencin, Martin, SK; Rotterdam, NL)

6. Immunomodulatory effect and mechanism of tuftsin in inflammatory bowel disease
   C. Chen (Shanghai, RC)

7. Colorectal and rectocolic reflexes in canines: Involvement of tone, compliance and anal sphincter relaxation
   J.-H. Chen, J.D.Z. Chen (Wuhan, RC; Galveston, USA)

8. Gastric electrical stimulation reduces visceral sensitivity to gastric distention in healthy canines
   J.-H. Chen, J.D.Z. Chen (Wuhan, RC; Galveston, USA)

9. Traditional Chinese physician pattern of syndrome and correlation shown by the colonoscope of part of ulcerative colitis in Urumqi
   J. Chen, H. Wang (Urumqi, RC)
10. Structural shifts of gut flora in rat acute alcoholic liver injury and Jianpihuoxue decoction’s effect displayed by ERIC-PCR fingerprint
   Y. Cheng, H. Wang, Y. Hu, G. Chen, J. Ping, J. Pen, Q. Fen (Shanghai, RC)

11. Capsule enteroscopy diagnostic yield for chronic abdominal pain
    J. Derova, A. Derovs, S. Sitkin, J. Pokrotnieks (Riga, LV; St. Petersburg, R)

12. Quality of bowel cleansing level before video capsule endoscopy, using most popular bowel cleansing scheme
    A. Derovs, J. Derova, S. Sitkin, J. Pokrotnieks (Riga, LV; St. Petersburg, R)

13. High depression and anxiety scores in a systematic review of psychological questionnaires in irritable bowel syndrome

14. NKKX2-3 rs10883365 is associated with disease susceptibility to both Crohn’s disease and ulcerative colitis while IRGM rs13361189 variant allele increased the risk for Crohn’s disease in Eastern European patients

15. Increased intestinal permeability to iohexol as a marker of disease activity in patients with inflammatory bowel disease
    V. Gerova, D. Svinarov, S. Stoynov (Sofia, BG)

16. Proliferating cell nuclear antigen (PCNA) is associated with dysplasia in ulcerative colitis
    K. Guzinska-Ustymowicz, A. Pryczynicz, M. Ustymowicz, M. Sokolowski, A. Kemona (Bialystok, PL)

17. The natural history of adult Crohn’s disease in China
    J. Hu, Q. Mei, J. Xu (Hefei, RC)

18. Study on the correlation of colonic pathologic changes due to ulcerative colitis and tongue proper, tongue four and pulse condition
    J. Han (Zhengzhou, RC)

19. The estimation of late rectal mucosal damage after conformal radiotherapy for prostate carcinoma
    P. Kedzierawski, T. Wollny, A. Salata (Kielce, PL)

20. The clinical and molecular features of ulcerative colitis related colon cancer
    J. Li, W. Zheng, J.-M. Qian (Beijing, RC)
21. Prevention of colonic fibrosis by taurine in rats with colitis induced by 2,4,6-trinitrobenzene sulphonic acid
L. Lin, J. Cheng, Y. Ning, W. Zhang, H. Zhang (Nanjing, RC)

22. The clinical value of miniature ultrasonic probes on diagnosis and treatment of digestive tract diseases
P. Liu (Jiangsu, RC)

23. The study of intestinal mucosal permeability of ulcerative colitis patients
X. Liu, Q. Mei, J. Xu, J. Jin, Q. Xia, D. Xu, J. Hu (Hefei, RC)

24. Effects of military training on food intake-related changes of automatic nervous system in new college students
X. Liu, Z. Li, Q. Zhang, C. Zhang, J.-H. Chen (Wuhan, RC)

25. Foxp3+ IL-17+ T cells in inflammatory intestinal mucosa show inflammatory features
Z. Liu, J. Su, X. Wang, P.-C. Yang (Shanghai, RC; Hamilton, CDN)

26. Downregulation of survivin by RNAi inhibits the growth of human gastric carcinoma cells SGC7901
Q.-M. Lu, G.-Y. Miao (Lanzhou, RC)

27. Practices of using methotrexate as monotherapy and in combination with azathioprine in patients with ulcerative colitis
P. Makarchuk (Moscow, R)

28. Improved quality-of-life in Crohn’s disease after the intake of a probiotic
P. Nikolov, D. Panova (Sofia, BG)

29. Alterations of CRP in patients with inflammatory bowel disease after the intake of a probiotic
P. Nikolov (Sofia, BG)

30. Diagnostic criteria of IBD
Q. Ouyang, L.-Y. Xue (Chengdu, RC)

31. The role of complementary alternative medicine in inflammatory bowel disease – Focus on Traditional Chinese Medicine in UC
Y. Pan, Q. Ouyang, X. Chen, C. Ye (Chengdu, RC)

32. Capsule enteroscopy small bowel transit time doesn’t correlate with vital signs
J. Pokrotnieks, J. Derova, S. Sitkin, A. Derovs (Riga, LV; St. Petersburg, R)

33. Comparative studies on the PCNA expression in inflammatory bowel diseases and colorectal cancer
A. Pryczynicz, K. Guzinska-Ustymowicz, M. Ustymowicz, M. Sokolowski, A. Kemona (Bialystok, PL)
34. Results of surgery in carcinoma rectum with sphincter preservation  
   M. Sahni, S. Jain, K.S. Sodhi (Hoshiarpur, IND)

35. Delayed gastric emptying in Indonesian population with reflux esophagitis  
   D. Samosir, L.A. Lesmana, M. Abdullah (Jakarta, RI)

36. Crohn’s disease in the Endoscopic Unit, Division of Gastroenterology, Department 
   of Internal Medicine, Cipto Mangunkusumo General Hospital, Jakarta in the 
   year 2007–2008  
   M. Simadibrata, D.D. Kansera, J. Estherina, N.P.H. Lugito, R. Yaruntradhani, F. Hardi, 
   N. Ista, M. Abdullah, A. Fauzi, D. Hardjodisastro, A.A. Rani, E. Krisnohani, 
   D.R. Handjari (Jakarta, RI)

37. Evaluation of Ki-67 and PCNA expression in Crohn’s disease  
   M. Sokolowski, K. Guzinska-Ustymowicz, A. Pryczynicz, M. Ustymowicz, 
   A. Kemona (Bialystok, PL)

38. Clinical study on effect of compound glutamin entersolube capsule combined 
   clysis therapy on ulcerative colitis  
   H. Tan, M.-Y. Sun, J. Yang (Tianjin, RC)

39. Epidemiological prospective study in inflammatory bowel disease in Aljarafe 
   region (Seville)  
   Y. Torres Dominguez, F.J. Mendoza Olivares, F.J. Garcia Fernandez, F.J. Alcazar 
   Guijo, J.M. Infantes Hernandez, J.M. Catalan Ramirez (Seville, E)

40. Clinical and epidemiological characteristics of Crohn’s disease, depending on 
   age at onset  
   Y. Torres Dominguez, F.J. Garcia Fernandez, F.J. Mendoza Olivares, J.M. Catalan 
   Ramirez, F.J. Alcazar Guijo, J.M. Infantes Hernandez (Seville, E)

41. Duodenal histologic alterations in lactose intolerance  
   Y. Torres Dominguez, F.J. Garcia Fernandez, F.J. Mendoza Olivares, J.M. Catalan 
   Ramirez, F.J. Alcazar Guijo, J.M. Infantes Hernandez, (Seville, E)

42. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of 
   disease activity in patients with Crohn’s disease  
   T.G. Toth, P. Fuszek, L.S. Kiss, K. Palatka, I. Altorjay, P. Antal-Szalmas, E. Palyu, 
   M. Udvardy, T. Molnar, K. Farkas, J. Papp, M. Papp, P.L. Lakatos (Budapest, 
   Debrecen, Szeged, H)

43. Ki-67 overexpression in Crohn’s disease, colitis ulcerosa and colorectal 
   adenocarcinoma  
   M. Ustymowicz, A. Pryczynicz, K. Guzinska-Ustymowicz, A. Kemona (Bialystok, PL)

44. Therapeutic effect of CXCR4 antagonist AMD3100 on experimental colitis 
   induced by DSS in mice  
   F. Wang, X. Xia (Nanjing, RC)
45. The role of enteral nutrition in adult Crohn’s disease patients  
   L. Wang, J. Guo, G. Zhang (Wuxi, RC)

46. The curative effect of moderate and severe ulcerative colitis treated by mesalazine 
   combined with Tripterygium hypoglaucum Hutchins  
   L. Wang, Y.-S. Xiang, R. Jiang, C.-Q. Liu (Jingmen, RC)

47. The frequency and function of Th-17 cells producing IL-17A in inflammatory bowel disease  
   Y. Wang, X. Liu, Z. Zhao, J. Chen, C. Yu (Nanjing, RC)

48. The prevalence status of inflammatory bowel disease in China  
   Y. Wang, Q. Ouyang, R. Hu (Chengdu, RC)

49. Human intestinal lamina propria CD4+CD25++ T regulatory cells (Treg) can be expanded in vitro with retention of potent suppressor function  
   Z. Wen, Q. Ouyang, G. West, C. Fiocchi (Chengdu, RC; Cleveland, USA)

50. Hypoxia in perspective from inflammatory bowel disease to colorectal cancer – Study of hypoxia-inducible protein. EPO serum levels as prognostic marker of survival of colorectal cancer patients  
   A. Wincewicz, A. Pietrzykowski, L. Kanczuga-Koda, M. Baltaziak, M. Sulkowska, M. Koda, W. Famulski, S. Sulkowski (Bialystok, PL)

51. A case-control study on dietary and living style factors for the development of inflammatory bowel disease in Hunan province  
   X. Wu, Y. Mo, X. Liu (Changsha, RC)

52. Expression of proteinase-activated receptor-2 in intestinal mucosa of patients with ulcerative colitis  
   Z.-X. Wu (Hefei, RC)

53. Effect of total glucosides of paeony on oxazolone-induced colitis in mice  
   J. Xiang, R. Hu, Q. Ouyang (Nanchong, Chengdu, RC)

54. Role of endoscopy and histopathology in distinguishing between Crohn’s disease and intestinal tuberculosis in Kunming, China  
   Y. Xiao, Y. Miao, Y. Du, P. Pu (Kunming, RC)

55. Follow-up of surgical treatment for ulcerative colitis  
   S. Yang, R. Li, W. Fu (Beijing, RC)

56. The relationship between tumor necrosis factor-α and ulcerative colitis  
   Y. Yang (Harbin, RC)

57. Diagnosis of obscure gastrointestinal hemorrhages with capsule endoscopy in the different ages  
   B.-L. Zhang, C.-X. Chen, Y.-M. Li (Hangzhou, RC)
58. The effect of military training impact on freshmen’s electrogastrogram (EGG)
Q. Zhang, Z. Li, C. Zhang, X. Liu, J.-H. Chen (Wuhan, RC)

59. Expression and clinical significance of GAFP and COX-2 in the colonic mucosa
of patients with ulcerative colitis and irritable bowel syndrome
Y.-Q. Zhong, R. Yan (Guangzhou, RC)

60. HIV protease inhibitors induce gut microbial translocation and systemic
inflammation by disrupting intestinal epithelial barrier integrity through
activating the ER stress response
H. Zhou, Y. Huang, X. Li, E. Studer, W.M. Pandak, P.B. Hylemon (Richmond, USA;
Wenzhou, RC)

61. The quantitative analysis of the contrast-enhanced ultrasonography in colorectal
carcinomas
H. Zhuang, Z.-G. Yang (Chengdu, RC)

Liver

62. The amount of alcohol consumption negatively impacts short-term mortality in
patients with alcoholic hepatitis: Clinical implications
J. Altamirano, F. Higuera, A. Duarte-Rojo, M. Martinez, L. Herrera, J.G. Abraldes,
L. Zapata, M. Dominguez, P. Ginès, J. Caballeria, R. Bataller (Barcelona, E;
Mexico City, MEX)

63. Hepatitis B virus genotypes and subtypes among chronic hepatitis B, liver
cirrhosis and hepatocellular carcinoma patients in Pekanbaru, Indonesia
A. Arfianti, A. Zainal, R. Endriani, F. Andrini (Pekanbaru, RI)

64. Value of large volume paracentesis in management of ascitic patients with
acute variceal bleeding
A. Bahnacy, M. Alserafy (Menoufiya, Cairo, ET)

65. State hepatobiliary system in children with obesity and metabolic syndrome
T.A. Bokova (Moscow, R)

66. Effects of ursodeoxycholic acid in treatment of children with metabolic syndrome
T.A. Bokova (Moscow, R)

67. The value of MESO (MELD/Na index) scoring system in predicting prognosis of
patients with cirrhosis
L. Chen, N. Hu, Y. Wang (Hefei, RC)

68. The clinical analysis of 82 patients with drug-induced liver injury
C.-L. Cong, B.-Z. Su (Hohhot, RC)
69. Clinical features and effects of ursodeoxycholic acid on Chinese patients with primary biliary cirrhosis
W.-J. Duan, X.-J. Ou, F.-K. Zhang, H. You, H. Ma, J.-D. Jia (Beijing, RC)

70. Frequent hypermethylation of the 14-3-3 sigma gene in human hepatitis B virus-related hepatocellular carcinoma
Y.-F. Gao, Q. Su, J.-B. Li, X. Li (Hefei, RC)

71. Small intestinal dysmotility and bacterial overgrowth in patients with liver cirrhosis
V. Gerova, S. Stoynov (Sofia, BG)

72. Attenuation of hepatic triglyceride accumulation and insulin resistance in ob/ob mice by macrophage (Kupffer cell)-specific overexpression of cholesteryl ester hydrolase
S. Ghosh, J. Bie, B. Zhao (Richmond, USA)

73. Beta lipoprotein faster migration is sensitive parameter for acute and chronic active hepatitis
K. Hameed Hassan (Basra, IRQ)

74. The role of TGF-βs expressed by biliary epithelial cells in the pathogenesis of cholestatic liver disease
Y. He, B.-L. Chen, R.-P. Yang, Z.-R. Zeng, M. Ren (Guangzhou, RC)

75. Analysis of risk factors of patients with chronic liver failure complicated invasive fungal infections
A.-R. Hu, J. Tan (Ningbo, RC)

76. Short-term efficacy and safety of standard interferon with a low accelerating dosage regimen in HCV-related decompensated cirrhotics
F. Ji, H. Deng, Z. Cai, H. Xue, C. Tian (Xi’an, RC)

77. Waist-to-hip ratio is a superior predictor for nonalcoholic fatty liver disease

78. Abdominal ultrasound accurately detects complications in patients with hepaticojejunooanastomosis
I. Kajzrlikova, P. Vitek, J. Chalupa (Frydek-Mistek, CZ)

79. The correlation between liver stiffness and serum markers of fibrosis in patients with chronic hepatitis B
V. Kawengian, B.J. Waleleng, N. Tendean Wenas, L. Rotty, M. Abdullah, A.A. Rani (Manado, Jakarta, RI)

80. Stimulation of human hepatic stellate cells by cytochrome P4502E1-mediated oxidative stress
J. Li, T.-H. Liu, H. You, Y.-Q. Xu (Beijing, RC)
81. The role and clinical significance of hepatic stellate cells in hepatocellular carcinoma
L. Li, L. Yang, J. Ye, B. Wang, W. Zhou, X. Hou (Wuhan, RC)

82. Adjuvant gene therapy followed by orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) beyond the Milan criteria – A prospective study
L. Li (Beijing, RC)

83. Analysis of 42 potential antiviral resistance mutation sites of HBV reverse transcriptase in chronic HBV infection patients with nucleos(t)ide treatment
X.-G. Li, J. Xu, T. Li, J.-X. Yang, B.-M. Liu, L. Li (Beijing, RC)

84. Expression of leptin and its correlation with component of extracellular matrix in hepatic fibrosis
C. Lu, J. Xu (Nantong, RC)

85. Liver injury in experimental sepsis: The late phase effects of hyperbaric and normobaric oxygen therapies

86. The role of heme oxygenase-1 on nutritional steatohepatitis in mice
Y.-M. Nan, R.-Q. Wang, W.-J. Wu, B.-L. Liang, S.-X. Zhao, N. Fu, J. Yu (Shijiazhuang, RC)

87. Viral hepatitis in patients with chronic renal insufficiency on hemodialysis
O.B. Nepesova, A.G. Japarova, H.E. Blum (Ashgabat, XTU; Freiburg, D)

88. Adipose tissue-derived MSCs are an eligible option to human hepatocytes

89. Predictors of development hepatocellular carcinoma in chronic hepatitis C
S. Pavic, G. Lucic (Uzice, SRB)

90. Quality of life in patients with chronic hepatitis C after antiviral therapy
S. Pavic, N. Svirtlih, D. Delic, J. Simonovic (Uzice, Belgrade, SRB)

91. Treatment of severe hepatitis with transplantation of autologous bone-marrow stem cells in human
Y. Peng, D. Hu, S. Wang (Beijing, RC)

92. MMP-9 and TNF-α as factors implicated in pathogenesis of autoimmune hepatitis type 1
C.A. Silosi, I. Silosi, V. Biciusca (Craiova, RO)

93. Clinical utility of autoantibodies in liver disease patients
I. Silosi, C.A. Silosi, V. Biciusca, F. Petrescu (Craiova, RO)
94. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure
   L.-J. Sun, J.-W. Yu, Y.-H. Zhao, P. Kang, S.-C. Li (Harbin, RC)

95. Active state of T lymphocytes and expression of CD45RA, CD45RO and CXCR3 of liver infiltrating lymphocytes and peripheral blood mononuclear cells in primary biliary cirrhosis

96. Expression of pituitary homeobox 1 gene in human hepatocellular carcinoma and its clinic pathological significance
   B. Wang, J. Ye, L. Li, W. Zhou, L. Yang, X. Hou (Wuhan, RC)

97. The clinical features of parenteral nutrition-associated cholestasis (PNAC) in preterm infants
   C. Wang, L. Shi, Z. Chen (Xi’an, RC)

98. Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single centre
   J. Wang, L.-B. Xu, C. Liu, H.-W. Pang, Y.-J. Chen, J.-S. Chen, Q.-J. Ou (Guangzhou, RC)

99. Management experiences for portal vein thrombosis in liver transplantation
   Z.-X. Wang, H. Yin, G.-S. Ding, Z.-R. Fu (Shanghai, RC)

100. Altered gene profile of placenta from women with intrahepatic cholestasis of pregnancy
    J. Wei, H. Wang, X. Yang, M. Dong, Z. Wang (Hangzhou, RC)

101. Case report of 5 patients with hepatic veno-occlusive disease induced by herbs and literature review

102. Fuzheng Huayu formula inhibits activation of primary hepatic stellate cells through inhibiting apoptosis of primary hepatocytes
    X. Yan, Q. Wang, Y. Ran, C. Liu (Shanghai, RC)

103. Biliary decompression strategies in relation to acute suppurative cholangitis with intestinal dysfunction

104. Logistic regression analysis of risk factors on hepatitis B-related liver cirrhosis complicated by hepatorenal syndrome
    J.-S. Yang, C.-S. Wang, S.-B. Yang, J.-H. Yang, Y.-L. Yu (Wuhu, RC)
105. Clinical analysis of 94 cases with Budd-Chiari syndrome
   L. Yang, S. Tang, J. Ye, X. Hou (Wuhan, RC)

106. Analysis of clinical features and prognostic factors in inpatients with nonalcoholic fatty liver disease
   Y.-T. Yao, W.-H. Sha, Q.-Y. Wang, R.-Y. Cen, Y. Zheng (Guangzhou, RC)

107. Anti-inflammatory effects of Traditional Chinese Medicine on nonalcoholic steatohepatitis
   L. Ying, B.-D. Lu, L.-Q. Guo, C.-M. Jiang (Dalina, RC)

108. Analysis of the efficacy of treatment with peginterferon α2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus
   J.-W. Yu, L.-J. Sun, Y.-H. Zhao, P. Kang, S.-C. Li (Harbin, RC)

109. Effects of grape extract on endoplasmic reticulum stress-induced apoptosis
   J. Yu, V. Khaoustov, Y.-M. Xu, B. Yoffe (Nanning, RC; Houston, USA)

110. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumour thrombi

111. An experimental study on the relationship between 5-hydroxytryptamine (5-HT) and human hepatocellular carcinoma

112. Antibiotics in primary prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients with ascites: A meta-analysis
    Y.-D. Zhong, Y.-F. Yang, W.-M. Lu, P. Huang, N. Zhang (Nanjing, RC)
List of Speakers, Moderators, Scientific Organizers and Consultants

Prof. Dr. Vicente Arroyo-Perez
Hospital Clinico y Provincial
Universidad de Barcelona
Unidad de Hepatología
Villarroel 170
08036 Barcelona
Spain
varroyo@clinic.ub.es

Dr. W. Bemelman
Universiteit van Amsterdam
Academisch Medisch Centrum
Department of Surgery
Meibergdreef 9
1105 AZ Amsterdam
Netherlands
w.a.bemelman@amc.uva.nl

Dr. Charles N. Bernstein
University of Manitoba
Department of Gastroenterology
804 F-175 McDermot Avenue
Winnipeg MB R3E 3P4
Canada
cbernst@cc.umanitoba.ca

Prof. Dr. Cheng-Wei Chen
85th Hospital of PLA
Liver Disease Research Center
9585 Humin Road, Xuhui Distr.
200235 Shanghai
P. R. China
ccw2@163.com

Prof. Dr. Jun Cheng
Beijing Ditan Hospital
Department of Infectious Disease
No. 8 Jingshundong Street
100011 Beijing
P. R. China
jun.cheng.ditan@gmail.com

Prof. Dr. Massimo Colombo
Ospedale Maggiore
IRCCS Policlinico
Dipartimento di Gastroenterologia ed Encocrinologia
Via Francesco Sforza, 35
20122 Milano
Italy
massimo.colombo@unimi.it

Adrian M. Di Bisceglie, M.D.
Professor of Medicine
Saint Louis University
School of Medicine
Gastroenterology & Hepatology
3635 Vista Ave. at Grand Blvd.
St. Louis MO 63110-0250
USA
dibiscam@slu.edu

Prof. Dr. Dai-Ming Fan
Xijing Hospital
Institute of Digestive Diseases
15 Western Changle Road
710032 Xi’an, Shanxi Province
P. R. China
fandaim@fmmu.edu.cn

Prof. Dr. Jia Fan
Zhongshan Hospital
Shanghai Fudan University
Department of Hepatology Surgery
180 Fenglin Road, Xuhui Distr.
200032 Shanghai
P. R. China
jiafang99@yahoo.com

Judy Cho, M.D.
Yale University
School of Medicine
Department of Internal Medicine
333 Cedar Street
New Haven CT 06520
USA
judy.cho@yale.edu
Prof. Dr. Geoffrey C. Farrell  
The Canberra Hospital  
Bldg. 10, Level 5  
P. O. Box 11 Woden  
Canberra ACT 2606  
Australia  
geoff.farrell@act.gov.au

Prof. Dr. Stefan Feuerbach  
Röntgendiagnostik  
Klinikum der  
Universität Regensburg  
93042 Regensburg  
Germany  
stefan.feuerbach@klinik.uni-regensburg.de

Prof. Dr. Qing-Chun Fu  
85th Hospital of PLA  
Department of Hepatology  
9585 Humin Road, Xuhui District  
200235 Shanghai  
P. R. China  
qcfu85@163.com

Dr. E. J. Gane  
Auckland City Hospital  
Liver Transplant Unit  
P. O. Box 92024  
Auckland  
New Zealand  
edgane@adhb.govt.nz

Prof. Dr. Peter R. Gibson  
Box Hill Hospital  
Dept. of Gastroenterology  
Box Hill VIC 3128  
Australia  
peter.gibson@med.monash.edu.au

Prof. Dr. Pere Ginès  
Hospital Clinico y Provincial  
Universidad de Barcelona  
Unidad de Hepatologia  
Villarroel 170  
08036 Barcelona  
Spain  
pgines@clinic.ub.es

Gregory J. Gores, M.D.  
Professor of Medicine  
Mayo Clinic  
Division of Gastroenterology & Hepatology  
200 First Street SW  
Rochester MN 55905  
USA  
gores.gregory@mayo.edu

Dr. Kwang-Hyub Han  
Yonsei University  
College of Medicine  
Department of Internal Medicine  
134, Shinchon-dong, Seodaemun-ku  
120-752 Seoul  
Korea  
gihhankhys@yumc.yonsei.ac.kr

Stephen B. Hanauer, M.D.  
Professor of Medicine  
University of Chicago  
Department of Medicine  
Gastroenterology Section  
5841 S. Maryland Ave.  
Chicago IL 60637-1463  
USA  
shanauer@medicine.bsd.uchicago.edu

Prof. Dr. Dieter Häussinger  
Gastroenterologie/Hepatologie  
Universitätsklinikum Düsseldorf  
Moorenstr. 5  
40225 Düsseldorf  
Germany  
haeussin@uni-duesseldorf.de

Prof. Dr. Toshifumi Hibi  
Keio University  
School of Medicine  
35, Shinano-machi  
Shinjuku-ku Tokyo 160-8582  
Japan  
thibi@sc.itc.keio.ac.jp
Stephen R. Targan, M.D.
Professor of Medicine
Cedars-Sinai Medical Center
Davis Research Center
#D-4063 (1865)
8700 Beverly Blvd.
Los Angeles CA 90048
USA
targans@cshs.org

Dr. M.-H. Tsai
Chang Gung University
Division of Gastroenterology
199, Tung Hwa North Road
10591 Taipei
Taiwan
mhtsai@cgmh.org.tw

Dr. Gui-Qiang Wang
Beijing Medical University
First Teaching Hospital
Department of Hepatopathy
8 Xishiku Street, Xicheng Distr.
100034 Beijing
P. R. China
wangqq@hotmail.com

Prof. Dr. Mamoru Watanabe
Tokyo Medical & Dental University
School of Medicine
Department of Gastroenterology
1-5-45, Yushima, Bunkyo-ku
Tokyo 113-8519
Japan
mamoru.gast@tmd.ac.jp

Dr. Lai Wei
People’s Hospital of
Beijing University
Department of Hepatopathy
11, Southern Street, Xizhimen
100044 Beijing
P. R. China
weelai@163.com

Prof. Dr. Florence Wong
University of Toronto
Toronto General Hospital
9EN/220
200 Elizabeth Street
Toronto ON M5G 2C4
Canada
florence.wong@utoronto.ca

Dr. Kai-Chun Wu
Xijing Hospital
Department of Gastroenterology
15 Western Changle Road
710032 Xi’an, Shanxi Province
P. R. China
kaicwu@fmmu.edu.cn

Prof. Dr. Bing Xia
Zhongnan Hospital
of Wuhan University
Department of Gastroenterology
169 Donghu Road, Wuchang
430071 Wuhan
P. R. China
bingxia2004@yahoo.com.cn

Prof. Dr. Yao-Zong Yuan
Ruijin Hospital
Department of Digestive Diseases
197 Second Ruijin Road, Luwan
200025 Shanghai
P. R. China
yyz28@medmail.com.cn

Prof. Dr. Stefan Zeuzem
Innere Medizin I
Klinikum der Johann Wolfgang
Goethe-Universität Frankfurt
Theodor-Stern-Kai 7
60596 Frankfurt
Germany
stefan.zeuzem@kgu.de

Prof. Dr. Jia-Ju Zheng
Suzhou Municipal Hospital
Department of Gastroenterology
242 Guangji Road, Jinlv
215008 Suzhou
P. R. China
zhengjj2218@163.com
Congress Office
During the Falk Symposium 174
Shangri La’s Kerry Centre Hotel
1 Guang Hua Road
100020 Beijing
P. R. China
Telephone: +49(0)171/7 84 61 15
Telefax: +86(0)10/65 61 26 26

Opening Hours:
Thursday, August 26, 2010 16.00 – 21.00h
Friday, August 27, 2010 8.00 – 18.30 h
Saturday, August 28, 2010 8.30 – 18.30 h

Congress Fees
Scientific program of the Falk Symposium 174 € 200,-
Students and residents € 100,-

*** OR ***

Day ticket € 120,-
Students and residents € 60,-

The congress fees include:
- Welcome Evening on August 26, 2010
- Refreshments during coffee breaks
- Lunch on August 27 and 28, 2010
- A copy of the abstract volume

Admission to Scientific Events
For admission to scientific events your name badge should be clearly visible.

Congress Report
The official congress report of the Falk Symposium 174 “Gut and Liver” will be published in English in the first half of 2011 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Beijing.

Airport
International Airport Beijing
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
Falk Symposia and Workshops
nearly 250, attended by more than 100,000 participants from over 100 countries since 1967
Continuing medical education seminars
over 14,000, attended by more than one million physicians and patients in Germany alone
Comprehensive literature service for healthcare professionals and patients with more than 200 publications

Where medicine and pharmaceuticals meet – a tried and trusted link

www.falkfoundation.org www.drfalkpharma.com
Leinenweberstr. 5 79108 Freiburg Germany Tel +49 (0)761/1514-0 Fax +49 (0)761/1514-321 Mail zentrale@drfalkpharma.de
General Information:

FALK FOUNDATION e.V.

Leinenweberstr. 5
79108 Freiburg
Germany

Congress Division
Telephone: +49(0)761/1514-0
Telefax: +49(0)761/1514-359
E-mail: symposia@falkfoundation.de
www.falkfoundation.org

Co-sponsor:

Shenzhen Kangzhe Pharmaceutical Co., Ltd
6/F, 8/F, Building A,
Tsinghua Tongfang Information
Harbor No.11, Langshan Road
Nanshan District, Shenzhen, 518057
Phone: +86(0)755/82 41 68 68
Fax: +86(0)755/82 41 66 22
E-mail: ursofalk@cms.net.cn
Homepage: www.cms.net.cn